Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity (IL-7norm)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01784289|
Recruitment Status : Completed
First Posted : February 5, 2013
Last Update Posted : February 2, 2017
|Condition or disease|
|Lipodystrophy Obesity Type 2 Diabetes|
Rational: In reason of its ability to store fatty acids and to secrete numerous pro-inflammatory cytokines, the adipocyte appears as a key cell in the regulation of energy metabolism and immune response. Moreover, it has been recently shown that adipocytes play a role in the recruitment of cells involved in innate and adaptive immunity in adipose tissue.
White adipose tissue-related diseases are numerous, spreading from excess (obesity) to a complete (lipoatrophies) or partial lack (lipodystrophies), these 3 different disorders being paradoxically able to induce a metabolic insulin resistance syndrome.
Among the involved cytokines, interleukin-7 (IL-7), mostly known for its immune functions, also participates to the quantitative and qualitative balance of fat mass. Thus, IL-7 over-expression in an animal model induces a lipodystrophic syndrome with insulin resistance whereas in humans, a preliminary study shows that LMNA-linked lipodystrophies are associated with an increase of blood IL-7 levels. IL-7 also participates to reactivation of autoimmunity in patients suffering from auto-immune type 1 after islet transplantation.
Therefore, the aim of this study is to assess different cytokines, especially interleukin 7, and metabolic parameters levels as well as fat mass distribution, in different models of fat distribution, including normal-weighed, obese and lipodystrophic patients. A plasma serum, gene and tissue bank will be constituted in order to improve our knowledge in disorders linking fat mass, insulin resistance and immunity, especially in lipodystrophies, a rare monogenic model of insulin resistance.
Patients: The included patients correspond to subjects of either normal body weight, or obese, or suffering from lipodystrophic syndrome, whatever their type 2 diabetes status.
Methods: Blood IL-7 levels, other immune and/or pro-inflammatory cytokines, lymphocytes immuno-phenotype as well as metabolic parameters will be characterized. Fat mass will be assessed with non-invasive methods (DEXA and RMN). A plasma, serum and gene bank will be constituted. As well as an adipose tissue bank in patients who will have a surgery (especially plastic surgery in lipodystrophic patients), in order to cryo-preserve it and to define the inflammatory status of this tissue thanks to histological and molecular analysis.
Main judgment criteria: The main judgment criteria will be IL-7 blood levels in the different groups according to fat mass and metabolic parameters. The hypothesis is that in humans the quantitative and /or qualitative disturbances of adipose tissue are associated with an increase of IL-7 levels and the development of insulin-resistance.
Awaited results and possible implications: this study will allow to better delineate the immune and inflammatory component associated with alterations of fat mass distribution and glucose metabolism. Our approach combining clinical investigation and ex vivo and laboratory analysis is original and should allow to better understand the cellular mechanisms responsible for the inflammatory process originated in white adipose tissue and accompanying the disorders of this tissue- more especially lipodystrophic syndromes - opening new therapeutic perspectives in common human diseases (obesity, diabetes) on the one hand, and a rare disease (lipodystrophy) on the other hand.
|Study Type :||Observational|
|Actual Enrollment :||126 participants|
|Official Title:||Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophies According to Fat Mass and Glucose Metabolism|
|Study Start Date :||June 2010|
|Actual Primary Completion Date :||June 2015|
|Actual Study Completion Date :||June 2015|
Patients with no overweight and no type 2 diabetes
patients with a lipodystrophy, most are diabetics
obese non diabetics
Patients with obesity (BMI <30kg/m2), without diabetes
Patients with obesity (BMI <30 kg/m2), with diabetes
- Measure of blood Interleukin 7 [ Time Frame: 1 day ]
- measure of blood Interleukins 2 [ Time Frame: 1 day ]
- measure of blood interleukin 9 [ Time Frame: 1 day ]
- measure of blood Interleukin 15 [ Time Frame: 1 day ]
- measure of blood TNF [ Time Frame: 1 day ]
- measure of blood IL-1 [ Time Frame: 1 day ]
- measure of blood IL-6 [ Time Frame: 1 day ]
- measure of blood IL-8 [ Time Frame: 1 day ]
- measure of blood IL-10 [ Time Frame: 1 day ]
- measure of blood IL-18 [ Time Frame: 1 day ]
- measure of blood leptin [ Time Frame: 1 day ]
- measure of blood adiponectin [ Time Frame: 1 day ]
- Blood count of monocytes/macrophages [ Time Frame: 1 day ]
- Blood count of dendritic cells [ Time Frame: 1 day ]
- Count of blood lymphocytes T [ Time Frame: 1 day ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01784289
|Amiens University Hospital|
|Amiens, France, 80054|
|Caen University Hospital|
|Caen, France, 14032|
|Lille University Hospital|
|Lille, France, 59037|
|Reims University Hospital|
|Reims, France, 51092|
|Rouen University Hospital|
|Rouen, France, 76031|
|Principal Investigator:||marie christine VANTYGHEM, pHd||Lille University Hospital|